Text Size

A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension

This study has been completed.
Sponsor:
Information provided by:
Alcon Research
ClinicalTrials.gov Identifier:
NCT00372931
First received: September 6, 2006
Last updated: April 21, 2008
Last verified: April 2008
History of Changes
  Purpose

The purpose of this study is to determine whether AL-37807 is safe and effective in treating patients with open-angle glaucoma or ocular hypertension


Condition Intervention Phase
Open-Angle Glaucoma
Ocular Hypertension
 Drug: AL-37807
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Mean IOP change from baseline

Estimated Enrollment: 120
Study Start Date: May 2006
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients of either sex and any race with open-angle glaucoma or ocular hypertension; logMAR visual acuity not worse than 0.60; additionally clinically relevant ophthalmic or systemic conditions may be excluded

Exclusion Criteria:

  • Under 18
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00372931

Locations
United States, Texas
San Antonio Site
San Antonio, Texas, United States, 78240
Sponsors and Collaborators
Alcon Research
Investigators
Study Director: Theresa Landry Study Director
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00372931     History of Changes
Other Study ID Numbers: C-06-15
Study First Received: September 6, 2006
Last Updated: April 21, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Hypertension
Ocular Hypertension
 Eye Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 23, 2013